Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy.
BACKGROUND
Hepatic steatosis may develop after pancreatic resection, but its clinicopathological features remain unclear. We explored the clinical characteristics of newly appearing nonalcoholic fatty liver disease (NAFLD) after pancreaticoduodenectomy (PD), designated as de novo NAFLD after PD.


METHODS
Of 83 patients who underwent PD between 2001 and 2006, the patients with regular alcohol consumption after PD (n = 3), those who were unavailable for regular abdominal computed tomography follow-up (n = 12), and those who died within 6 months of PD (n = 8) were excluded from the study. In the remaining 60 patients, the prevalence and clinical features of de novo NAFLD after PD were examined.


RESULTS
NAFLD developed after PD in 14 (23%) patients in our cohort. Liver biopsy was performed in 8 patients and all showed typical steatohepatitis. Compared with the patients who had conventional nonalcoholic steatohepatitis (NASH), patients with post-PD de novo NASH demonstrated significant decreases in body mass index and lower levels of serum albumin, cholesterol, apolipoprotein B, and homeostasis model assessment for insulin resistance. Multivariate logistic regression analysis revealed that pancreatic head cancer was associated with an increased risk of developing NAFLD after PD (odds ratio 12.0, 95% confidence interval 2.0-71.4, P = 0.006). Increased dosage of oral pancreatic enzymes significantly ameliorated the steatosis, as well as leading to the recovery of body weight loss and resolution of the biochemical abnormalities.


CONCLUSIONS
De novo NAFLD/NASH after PD is characterized by non-obesity and lack of hyperlipidemia and insulin resistance and is associated with pancreatic exocrine insufficiency. In such patients, intensifying pancreatic enzyme supplementation may be useful.
Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan. tanakan@mail.nih.gov
Naoki
N
Tanaka
Akira
A
Horiuchi
Takahide
T
Yokoyama
Gengo
G
Kaneko
Naoto
N
Horigome
Takahiro
T
Yamaura
Tadanobu
T
Nagaya
Michiharu
M
Komatsu
Kenji
K
Sano
Shin-Ichi
S
Miyagawa
Toshifumi
T
Aoyama
Eiji
E
Tanaka
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D057487:Enzyme Therapy; D004798:Enzymes / Q000008:administration & dosage; D005234:Fatty Liver / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016577:Pancreaticoduodenectomy / Q000009:adverse effects*; D015995:Prevalence; D014057:Tomography, X-Ray Computed; D055815:Young Adult
D004798:Enzymes
Ann Surg. 1991 Aug;214(2):131-40
1867520
AJR Am J Roentgenol. 2007 Dec;189(6):1484-8
18029889
Alcohol. 2008 Aug;42(5):349-61
18504085
J Lipid Res. 2008 May;49(5):1068-76
18227531
Liver Int. 2006 Oct;26(8):956-63
16953836
Clin J Gastroenterol. 2008 Oct;1(3):116-121
26193649
J Hepatol. 2010 Oct;53(4):724-31
20655124
J Clin Gastroenterol. 2008 Apr;42(4):413-8
18277895
J Clin Invest. 2008 Feb;118(2):683-94
18188449
J Hepatol. 2008;48 Suppl 1:S104-12
18304679
J Hepatol. 1997 Jul;27(1):108-13
9252082
J Gastroenterol. 2006 Aug;41(8):725-32
16988759
Acta Pathol Jpn. 1987 Dec;37(12):1953-60
2451395
J Hepatobiliary Pancreat Sci. 2010 May;17(3):296-304
19809782
J Hepatol. 2009 Jun;50(6):1236-46
19398233
Hepatology. 2005 Jun;41(6):1313-21
15915461
Am J Gastroenterol. 2008 Jan;103(1):245-6
18184133
Am J Surg. 1994 Jul;168(1):66-8
7912910
Hepatology. 2010 Sep;52(3):913-24
20648476
J Clin Gastroenterol. 2010 Jul;44(6):440-7
20104187
J Gastroenterol. 2010 Dec;45(12):1263-71
20625773
Hepatology. 2009 Oct;50(4):1241-50
19637192
J Hepatol. 2008 Nov;49(5):810-20
18620775
J Atheroscler Thromb. 2006 Aug;13(4):202-8
16908953
Liver Int. 2008 Sep;28(8):1104-11
18397231
Gastroenterology. 2002 Sep;123(3):745-50
12198701
J Hepatol. 2004 Jan;40(1):47-51
14672613
J Hepatol. 2002 Jul;37(1):154-60
12076877
J Gastroenterol. 2010 Jun;45(6):666-72
20084525